Cadence Pharmaceuticals, (FRA:QEW) Additional Paid-In Capital : €369.98 Mil(As of Dec. 2013)

View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, Additional Paid-In Capital?

Cadence Pharmaceuticals,'s quarterly additional paid-in capital declined from Jun. 2013 (€378.84 Mil) to Sep. 2013 (€375.65 Mil) but then stayed the same from Sep. 2013 (€375.65 Mil) to Dec. 2013 (€369.98 Mil).

Cadence Pharmaceuticals,'s annual additional paid-in capital increased from Dec. 2011 (€369.35 Mil) to Dec. 2012 (€377.54 Mil) but then declined from Dec. 2012 (€377.54 Mil) to Dec. 2013 (€369.98 Mil).

Cadence Pharmaceuticals, Additional Paid-In Capital Historical Data

The historical data trend for Cadence Pharmaceuticals,'s Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, Additional Paid-In Capital Chart

Cadence Pharmaceuticals, Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Additional Paid-In Capital

Get a 7-Day Free Trial

200.37

300.60

369.35

377.54

369.98

Cadence Pharmaceuticals, Quarterly Data
	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13
Additional Paid-In Capital	Get a 7-Day Free Trial															377.54	383.81	378.84	375.65	369.98

Cadence Pharmaceuticals, Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Cadence Pharmaceuticals, Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadence Pharmaceuticals, (FRA:QEW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cadencepharm.com

Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, (FRA:QEW) Headlines

No Headlines